Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.

John H Sampson | Robert J Schmittling | Gary E Archer | Kendra L Congdon | Smita K Nair | Elizabeth A Reap | Annick Desjardins | Allan H Friedman | Henry S Friedman | James E Herndon | April Coan | Roger E McLendon | David A Reardon | James J Vredenburgh | Darell D Bigner | Duane A Mitchell
PloS one | 2012

Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy. However, therapeutic approaches are complicated by the inadvertent inhibition of IL-2Rα expressing anti-tumor effector T-cells.

Pubmed ID: 22383993

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: P50 CA108786
  • Agency: NINDS NIH HHS, United States
    Id: P50 NS020023
  • Agency: NCI NIH HHS, United States
    Id: R01 CA097222
  • Agency: NCI NIH HHS, United States
    Id: R01-CA097222
  • Agency: NCRR NIH HHS, United States
    Id: UL1 RR024128
  • Agency: NCI NIH HHS, United States
    Id: P50-CA108786
  • Agency: NINDS NIH HHS, United States
    Id: R21 NS067980
  • Agency: NCI NIH HHS, United States
    Id: R21 CA132891
  • Agency: NCRR NIH HHS, United States
    Id: 1UL2-RR024128
  • Agency: NINDS NIH HHS, United States
    Id: P50-NS020023
  • Agency: NCI NIH HHS, United States
    Id: R21-CA132891
  • Agency: NINDS NIH HHS, United States
    Id: R21-NS067980

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


ClinicalTrials.gov (tool)

RRID:SCR_002309

Registry and results database of federally and privately supported clinical trials conducted in United States and around world. Provides information about purpose of trial, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals.Offers information for locating federally and privately supported clinical trials for wide range of diseases and conditions. Research study in human volunteers to answer specific health questions. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings. ClinicalTrials.gov contains trials sponsored by National Institutes of Health, other federal agencies, and private industry. Studies listed in database are conducted in all 50 States and in 178 countries.

View all literature mentions